Latest filingSep 04, 2026Most recent Form 4
PLX
Protalix BioTherapeutics, Inc.
Insider activity for last month from 08/04 to 09/04. Counts use processed Form 4 rows. Purchase and sale metrics use codes P and S; totals remain unknown when any matching value is missing. Rows without a usable transaction date cannot be assigned to a rolling period and are excluded.
Total buying$00 buys
Total selling$00 sells
Net open-market+$08 insiders
Open-market mix
Buy vs sell distribution by transaction countInsider activity report
Monthly open-market purchase and sale counts Buys Sells
Transaction codes
By Form 4 transaction code in selected period16transactions
- A · Grants / awards · dominant16 · 100%
Activity by reported role
A joint filing can contribute to multiple roles18transactions
- Director · dominant12 · 67%
- COO2 · 11%
- PRES2 · 11%
- SV2 · 11%
Distinct insiders active
Reporting-owner CIKs by month · peak Sep 2026 (8)Aug 2026Sep 2026
Reported Holdings After
Separated by insider, security, and ownership typeForster EliotStock Options (Right to Buy) · Direct
17,000Sep 03, 2026
Forster EliotRestricted Stock Units · Direct
8,500Sep 03, 2026
Ben Zvi ShmuelRestricted Stock Units · Direct
8,500Sep 03, 2026
Ben Zvi ShmuelStock Options (Right to Buy) · Direct
17,000Sep 03, 2026
Bar-Shalev AmosStock Options (Right to Buy) · Direct
17,000Sep 03, 2026
Bar-Shalev AmosRestricted Stock Units · Direct
8,500Sep 03, 2026
Bashan DrorRestricted Stock Units · Direct
160,000Sep 03, 2026
Bashan DrorStock Option (Right to Buy) · Direct
320,000Sep 03, 2026
These are reported post-transaction holdings, not company-wide ownership percentages. Securities, indirect vehicles, and amendments are kept separate.
Filing activity heatmap
Each cell is one day · intensity = transactions · buys green, sells redAug 04 → Sep 04
LessMore
Top insiders
By absolute net value across the selected period- NY+$0
- EC+$0
- MA+$0
- BF+$0
- BA+$0
Filing detail checks
Secondary metrics for the selected periodFiling-only signals
Deterministic matches in the selected period
No filing-only signal badges matched this period.
PLX transaction history
Filters apply within this company and selected period by default| Ticker | Insider | Role | Type | Shares | Value | Code | Signals | 90d return | Filed | Trans date |
|---|---|---|---|---|---|---|---|---|---|---|
| PLX | Naos Yaron | SVCOO | grant | 56.0k | $0 | A | — | — | 09/04 | 09/03 |
| PLX | Naos Yaron | SVCOO | grant | 112k | $0 | A | — | — | 09/04 | 09/03 |
| PLX | Elze Christian | DIR | grant | 8.50k | $0 | A | — | — | 09/04 | 09/03 |
| PLX | Elze Christian | DIR | grant | 17.0k | $0 | A | — | — | 09/04 | 09/03 |
| PLX | Melincoff Gwen A | DIR | grant | 8.50k | $0 | A | — | — | 09/04 | 09/03 |
| PLX | Melincoff Gwen A | DIR | grant | 17.0k | $0 | A | — | — | 09/04 | 09/03 |
| PLX | Boudes Pol F | DIR | grant | 8.50k | $0 | A | — | — | 09/04 | 09/03 |
| PLX | Boudes Pol F | DIR | grant | 17.0k | $0 | A | — | — | 09/04 | 09/03 |
| PLX | Bar-Shalev Amos | DIR | grant | 8.50k | $0 | A | — | — | 09/04 | 09/03 |
| PLX | Bar-Shalev Amos | DIR | grant | 17.0k | $0 | A | — | — | 09/04 | 09/03 |
| PLX | Bashan Dror | PRES | grant | 160k | $0 | A | — | — | 09/04 | 09/03 |
| PLX | Bashan Dror | PRES | grant | 320k | $0 | A | — | — | 09/04 | 09/03 |
| PLX | Ben Zvi Shmuel | DIR | grant | 8.50k | $0 | A | — | — | 09/04 | 09/03 |
| PLX | Ben Zvi Shmuel | DIR | grant | 17.0k | $0 | A | — | — | 09/04 | 09/03 |
| PLX | Forster Eliot | DIR | grant | 8.50k | $0 | A | — | — | 09/04 | 09/03 |
| PLX | Forster Eliot | DIR | grant | 17.0k | $0 | A | — | — | 09/04 | 09/03 |
Protalix BioTherapeutics, Inc. Insider Activity FAQ
SEC Form 4 contextWho recently reported transactions at Protalix BioTherapeutics, Inc.?
Naos Yaron, Elze Christian, Melincoff Gwen A, Boudes Pol F, Bar-Shalev Amos, Bashan Dror, Ben Zvi Shmuel, Forster Eliot.
When was the latest reported open-market purchase?
No code-P purchase is available for this period.
When was the latest reported open-market sale?
No code-S sale is available for this period.
What is the recent purchase and sale balance?
No code-P purchases or code-S sales were reported in the selected period.
Where can I see the original SEC filing?
Every transaction row and latest-activity fact links to its original SEC filing.
What do these Form 4 transaction codes mean?
P and S generally describe open-market or private purchases and sales. A, D, F, M, X, G, J, and V describe awards, issuer dispositions, tax withholding, exercises, gifts, other transactions, and voluntary early reports; review each filing and its footnotes for context.